Literature DB >> 29395604

Patterns and predictors of trajectories for social and occupational functioning in patients presenting with first-episode non-affective psychosis: A three-year follow-up study.

Wing Chung Chang1, Angel On Ki Chu2, Vivian Wing Yan Kwong2, Corine Sau Man Wong2, Christy Lai Ming Hui2, Sherry Kit Wa Chan3, Edwin Ho Ming Lee2, Eric Yu Hai Chen3.   

Abstract

BACKGROUND: Functional impairment is prevalent in patients with first-episode psychosis (FEP). Longitudinal course of functioning in the early stage of psychotic illness is under-studied. In this report, we aimed to investigate the patterns and baseline predictors of social-occupational functional trajectories over 3 years, utilizing growth mixture modeling (GMM) analysis, in a large representative Chinese young FEP cohort in Hong Kong.
METHOD: Six hundred seventeen consecutive patients aged 15-25 years presenting with first-episode non-affective psychosis to a specialized early intervention service were studied. Data on demographic, pre-treatment and baseline clinical characteristics were collected. Individual class membership of functioning derived from GMM was based on ratings on Social and Occupational Functioning Scale (SOFAS) measured at five different time-points (baseline, 6, 12, 24 and 36 months) across 3-year follow-up.
RESULTS: Four distinct functional trajectories were identified including persistently poor (48.1%, n = 320), early improved (31.3%, n = 203), gradually improved (14.8%, n = 69) and improved-deteriorated (5.8%, n = 25) trajectories. Multinomial regression analysis revealed that male gender, lower educational attainment, a diagnosis of schizophrenia-spectrum disorder and a receipt of inpatient treatment upon initial presentation independently predicted persistently poor trajectory membership.
CONCLUSION: The current study reveals a heterogeneous course of social-occupational functioning in FEP. Our finding that approximately half of the patients displaying persistently poor trajectory over 3 years indicates functional impairment as an unmet therapeutic need in early illness phase. Further research applying individual-based trajectory analysis in FEP is warranted to facilitate better characterization of longitudinal patterns of functioning and development of targeted intervention to promote early recovery.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  First-episode psychosis; Functional outcome; Growth mixture modeling; Longitudinal course

Mesh:

Year:  2018        PMID: 29395604     DOI: 10.1016/j.schres.2018.01.021

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  4 in total

1.  Longitudinal trajectory of early functional recovery in patients with first episode psychosis.

Authors:  Mei-Hua Hall; Kristina M Holton; Dost Öngür; Debra Montrose; Matcheri S Keshavan
Journal:  Schizophr Res       Date:  2019-02-28       Impact factor: 4.939

2.  Trajectories of occupational and social functioning in people with recent-onset non-affective psychosis enrolled in specialized early intervention services across New York state.

Authors:  Els van der Ven; Jennifer Scodes; Cale Basaraba; Luca Pauselli; Franco Mascayano; Ilana Nossel; Iruma Bello; Jennifer Humensky; Ezra Susser; Melanie Wall; Lisa Dixon
Journal:  Schizophr Res       Date:  2020-06-05       Impact factor: 4.939

Review 3.  First-episode psychosis: How long does it last? A review of evolution and trajectory.

Authors:  Jyoti Prakash; K Chatterjee; K Srivastava; V S Chauhan
Journal:  Ind Psychiatry J       Date:  2021-07-20

4.  Cognitive and Global Functioning in Patients With First-Episode Psychosis Stratified by Level of Negative Symptoms. A 10-Year Follow-Up Study.

Authors:  Magnus Johan Engen; Anja Vaskinn; Ingrid Melle; Ann Færden; Siv Hege Lyngstad; Camilla Bärthel Flaaten; Line Hustad Widing; Kristin Fjelnseth Wold; Gina Åsbø; Beathe Haatveit; Carmen Simonsen; Torill Ueland
Journal:  Front Psychiatry       Date:  2022-03-25       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.